ImmunityBio's shares shot up 28.74% recently, hitting $7.75 on the back of some hefty news. What’s driving this surge? It all starts with the European Commission giving the nod for ANKTIVA to treat bladder cancer, unlocking access in key markets like Saudi Arabia and beyond.
European Approval: A Game Changer?
This approval isn't just a stamp of approval; it's a potential game changer for ImmunityBio. They’ve moved quickly since their FDA green light, establishing a commercial presence across four regions in under two years. You can't ignore how crucial this is for them as they deepen their footprint in burgeoning markets.
But here’s the catch—the company must keep gathering safety data from ongoing trials to maintain that authorization. This isn't just busywork; it’s critical for keeping their product competitive in an aggressive marketplace.
The Technicals Are Mixed
Now let’s talk numbers—over the past year, ImmunityBio has gained 123.73%. The current trading price sits at $7.46, comfortably above both its 20-day and 200-day simple moving averages (SMAs). At first glance, that looks solid—but don't get too comfy yet.
The Relative Strength Index (RSI) is hovering around 56.81, signaling neutral sentiment among traders while the Moving Average Convergence Divergence (MACD) presents a bearish tone with its positioning below its signal line at 0.7993. While it seems bullish overall thanks to those moving averages being so far apart from where the stock is trading now, you can bet there are jitters beneath that surface.
